Clinical Trials Logo

Filter by:
  • Completed  
  • Page [1] ·  Next »
NCT ID: NCT03677583 Completed - Clinical trials for Gastrointestinal Complication

Duckweed Intake Study

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The study aims to study the impact of frequent intake of 150-180 gram duckweed on gastrointestinal complaints and several other health related biomarkers. The study has a randomised parallel design. Two different treatments will be evaluated e.g. a 11-day intervention with duckweed based meals and a 11-day intervention with control/spinach meals. At the start and at the end of the intervention we will collect a blood sample and a urine samples. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention.

NCT ID: NCT03664011 Completed - Healthy Clinical Trials

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Start date: September 10, 2018
Phase: Phase 1
Study type: Interventional

The main objectives of the study are as follows: - To assess the mass balance recovery of [14C]-radioactivity in urine and faeces after a single oral dose of 50 mg BI 730357 BS (C-14) in healthy male subjects - To provide plasma, urine, and faecal samples for metabolite profiling and structural identification

NCT ID: NCT03662763 Completed - Clinical trials for Attention Deficit Disorder

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity

Start date: September 2011
Phase: Phase 3
Study type: Interventional

A study to evaluate the long term maintenance of efficacy of using Guanfacine Hydrochloride (SPD-503) for the treatment of ADHD in Children aged 6-17 years in Europe, Australia, Canada and the US.

NCT ID: NCT03657446 Completed - Healthy Subjects Clinical Trials

A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

Start date: September 18, 2018
Phase: Phase 1
Study type: Interventional

The study will investigate whether administration of clazosentan can affect normal heart function in healthy subjects

NCT ID: NCT03654170 Completed - Healthy Clinical Trials

A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body

Start date: September 11, 2018
Phase: Phase 1
Study type: Interventional

This trial intends to investigate the basic pharmacokinetics of BI 425809 and [14C]- radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of 25 mg BI 425809 (C-14) given to healthy male subjects

NCT ID: NCT03643380 Completed - Overactive Bladder Clinical Trials

Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence

Start date: August 17, 2017
Phase: Phase 1
Study type: Interventional

A pre-market, prospective, non-randomized acute feasibility study for the treatment of patients with urinary incontinence (UI) as a consequence of urinary incontinence.

NCT ID: NCT03609775 Completed - Healthy Clinical Trials

A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

Start date: August 28, 2018
Phase: Phase 1
Study type: Interventional

A study to investigate the drug-drug interactions between ACT-541468 and ethanol in healthy subjects

NCT ID: NCT03596294 Completed - Healthy Subjects Clinical Trials

A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

Start date: July 19, 2018
Phase: Phase 1
Study type: Interventional

A study in healthy male subjects to investigate whether administration of rifampicin can affect the fate in the body (amount and time of presence in the blood) of clazosentan

NCT ID: NCT03580122 Completed - Clinical trials for Classic Galactosemia

The Effect of Arginine on Classic Galactosemia

Start date: December 5, 2017
Phase: Phase 2
Study type: Interventional

Rationale: Classic galactosemia is a rare inherited metabolic disease that presents in neonatal patients with a life-threatening multi-organ toxic syndrome. Although the current standard of care - a galactose-restricted diet - quickly relieves the severe neonatal clinical picture, it fails to prevent brain and gonadal sequelae. There is a need for new therapeutic strategies. As arginine is an amino acid that is therapeutically widely used with no side effects described, we propose to use it in a pilot-clinical study. We aim to evaluate the effects of arginine in classic galactosemia patients, in order to determine its potential therapeutic role in this disease. Objective: To evaluate the possible effect of arginine on the whole body galactose oxidative capacity in classic galactosemia patients. Study design: Interventional pilot-clinical study with pre-post single arm design. Study population: We aim to include 5 classic galactosemia adult patients homozygous for the p.Q188R mutation. Intervention: All participants will receive arginine in the form of Asparten ® (arginine aspartate) during 1 month, by oral administration. The main study parameter is whole body galactose galactose oxidative capacity.

NCT ID: NCT03578510 Completed - Clinical trials for Patients With End Stage Renal Disease on Hemodialysis

Effect of Plasma Sodium Concentration on Blood Pressure Regulators During Hemodialysis

Start date: September 17, 2012
Phase: N/A
Study type: Interventional

Intradialytic hypotension (IDH) is a frequent and serious complication that may occur during hemodialysis treatment. The investigators and others have shown that the Hemocontrol biofeedback system is associated with improved hemodynamic stability. Hemocontrol is a technique that guides the patients' blood volume along a pre-set trajectory by continuously adjusting the ultrafiltration rate and dialysate conductivity. In a recent pilotstudy, the investigators found significantly higher plasma vasopressin levels during the first hour of dialysis with Hemocontrol in comparison with standard hemodialysis. Increased vasopressin levels may contribute to intradialytic hemodynamic stability during hemodialysis by enhanced vasoconstriction. These results, however, did not prove directly that the improved hemodynamic stability with Hemocontrol is indeed caused by higher initial plasma vasopressin levels. Alternative explanations might be that 1) the higher initial plasma sodium levels with Hemocontrol dialysis enhance activity of the sympathetic nervous system directly, causing vasoconstriction and thereby improved hemodynamic stability and/or 2) that the higher initial plasma levels of sodium in Hemocontrol inhibit the release of nitric oxide by the vascular endothelium. Another goal of this study is to investigate whether vasopressin is removed with hemodialysis.